In 2005, Vamsi started his own company focused on data compliance for the pharmaceutical industry. His company provided technology to support clinical trials to the FDA. “I like to build companies, but I also like change. [After five years], I thought about selling the company and rolling it up into a publicly listed company.” He sold it in 2010 and moved to India to pursue new opportunities. While the sale was smooth, there were numerous post-sale challenges. “They basically ran down the company within 18 months.”

0:00 – 4:03 Vamsi’s background at Deloitte, Pfizer, Merrill Lynch

4:04 – 6:27 Acquiring Clinovo (how found and why chose over others)

6:28 – 9:24 Due diligence process as a buyer

9:25 – 11:24 Issues that came up during diligence process

11:25 – 13:39 Working with the investment banker

13:40 – 14:19 Interaction with seller prior to closing

14:20 – 19:19 Challenges with integration

19:20 – 21:55 Lessons learned and post-closing challenges

21:56 – 23:05 Lessons from the sell side

23:06 – 23:38 What’s on the horizon

M&A Science by Kison Patel (kison@dealroom.net)

DealRoom: Data Science and AI for M&A (www.dealroom.net)

Sell Side M&A Advice

M&A Science

Sell Side M&A Advice